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Abstract
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval 
of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson 
disease (PD). Therapies that intervene early in the disease continuum are a priority for the 
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many candidates in the drug development pipeline. There is a paucity of sensitive and objec-
tive, yet clinically interpretable, measures that can capture meaningful aspects of the disease. 
This poses a major challenge for the development of new therapies and is compounded by 
the considerable heterogeneity in clinical manifestations across patients and the fluctuating 
nature of many signs and symptoms of PD. Digital health technologies (DHT), such as smart-
phone applications, wearable sensors, and digital diaries, have the potential to address many 
of these gaps by enabling the objective, remote, and frequent measurement of PD signs and 
symptoms in natural living environments. The current climate of the COVID-19 pandemic cre-
ates a heightened sense of urgency for effective implementation of such strategies. In order 
for these technologies to be adopted in drug development studies, a regulatory-aligned con-
sensus on best practices in implementing appropriate technologies, including the collection, 
processing, and interpretation of digital sensor data, is required. A growing number of col-
laborative initiatives are being launched to identify effective ways to advance the use of DHT 
in PD clinical trials. The Critical Path for Parkinson’s Consortium of the Critical Path Institute is 
highlighted as a case example where stakeholders collectively engaged regulatory agencies 
on the effective use of DHT in PD clinical trials. Global regulatory agencies, including the US 
Food and Drug Administration and the European Medicines Agency, are encouraging the ef-
ficiencies of data-driven engagements through multistakeholder consortia. To this end, we 
review how the advancement of DHT can be most effectively achieved by aligning knowledge, 
expertise, and data sharing in ways that maximize efficiencies. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Parkinson disease (PD) is a devastating, chronic progressive disease for which new ther-
apies are urgently needed. The Global Burden of Disease Study reported in 2018 that PD is 
the fastest growing neurological disease [1]. That study estimated that in 2016 more than 6 
million people worldwide had PD, i.e., more than double the number of people with PD in 
1990 [1]. As the worldwide population ages, these numbers are expected to double again by 
about 2050 [2].
The scientific community’s understanding of PD has evolved considerably since the 
original description of the disease 200 years ago [3]. It is now understood to be a highly 
heterogeneous disease characterized by both motor and nonmotor symptoms, with under-
lying genetic and environmental etiologies. Growing evidence suggests that long before the 
manifestations of classical motor signs, such as bradykinesia, rigidity, and tremor, a prodromal 
phase takes place that is characterized, by among others, hyposmia, sleep disturbances, 
depression, and constipation [4, 5]. Identifying the disease in its earliest stages is a prereq-
uisite to slowing or stopping neurodegeneration and prevention. 
The growing prevalence of PD, combined with the lack of treatments that can delay or 
prevent the disease or adequately address nonmotor symptoms, emphasizes the urgency of 
accelerated and expanded treatment options for PD across the continuum of disease, particu-
larly in the earliest stages. Early intervention is a major focus to optimize the potential to 
delay or halt disease progression and it is a priority unmet need expressed by people living 
with PD [6, 7]. People living with PD express significant impairments in their quality of life 
based on a range of both motor and nonmotor symptoms. Innovative advances in genetics 
and new insights into the underlying pathophysiology of the disease have contributed to a 
rich pipeline of therapeutics that are now in development [8, 9]. However, PD drug devel-
opment faces many challenges, including heterogeneity of signs and symptoms both across 
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patients and – even within patients – across the disease continuum, a lack of biomarkers for 
patient selection and to quantify disease progression, large and heterogeneous placebo 
responses, and a high rate of failure of clinical trials [10]. Digital technologies are now being 
implemented in PD observational studies and clinical trials in both a passive and an active 
manner, and there is an opportunity to enable improved assessment of aspects of the disease 
that have been difficult to measure previously [11, 12].
Digital health technologies (DHT) have the potential to help address the challenges asso-
ciated with developing drugs for the treatment of PD. In this review, DHT are defined as a 
broad range of technologies that capture information about motor presentation and mobility, 
pathophysiological manifestations, cognitive decline, sleep, social interactions and behaviors, 
activity, speech, and mood (Table 1). The terminology of DHT was selected to align with that 
used by regulatory agencies including the US Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA). Categories of DHT include mobile health, health infor-
mation technology, wearable devices, telehealth, and remote trials. These mobile devices 
have the potential to assess behavioral, cognitive, and physiological aspects of a disease in a 
reliable, quantifiable, objective, and continuous manner. 
The effective use of DHT in clinical trials is a topic of growing interest due to their potential 
to improve outcome measures, aid in patient enrollment and stratification, enable monitoring 
of treatment adherence, enable collection of real-world data, and facilitate the implemen-
tation of remote trials [13]. However, successful deployment of DHT in PD clinical trials 
presents multiple challenges.
Challenges and Barriers to Advancing DHT for Use in PD Trials
As the rapidly evolving field of DHT moves forward, many challenges are emerging. The 
list below illustrates examples of barriers to be addressed or overcome at the present time, 
some which have been reviewed by others (e.g., [14, 15]).
 • Clinical relevance
 − Scarcity of reliable and frequent ground truth labels in real-world conditions, making it 
challenging to demonstrate clinical validity 
 − Challenges to extract clinically meaningful information from passive and actively 
collected digital device data 
 • Data and devices
 − The raw data can be complex, and meaningful signals must be filtered from a noisy 
background
 − Lack of standardized methods for collecting, storing, organizing, curating and analyzing 
data
 − Adapting DHT solutions to rapidly evolving aspects of the technology
 − Focal placement of biomechanical sensors in defined anatomic sites requires extensive 
validation to establish interpretable correlations with function, disability, and 
ultimately quality of life
 − Lack of a consensus on methods for establishing interchangeability of data obtained 
from different mobile devices and platforms developed by different manufacturers
 − Challenges of interoperability of data as hardware and software evolve over time; lack 
of a consensus and success for integration of digital device studies carried out across 
distinct and within individual platforms
 − Strategies for assessing the impact and adjusting for upgrades in hardware, software, 
and firmware are needed
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 • Patient population, privacy, and adherence
 − Issues with participant diversity, especially with regard to access and digital literacy
 − Patient and caregiver engagement, especially adherence to continued use of devices 
over time, is modest in some cases 
 − Lack of alignment on best practices to ensure the utmost compliance with patient privacy
 • Regulatory
 − Alignment on methods to establish reliability and validity of DHT measures
 − Health authority acceptance of fit-for-purpose DHT endpoints for clinical trials
The issues outlined above are difficult to address by any single individual entity. Precom-
petitive collaborations and public-private partnerships have been proposed as efficient 
means to address gaps in the development of DHT and their optimal use in drug development 
[16]. The opportunity to achieve a consensus among multidisciplinary stakeholders is one of 
the many reasons why public-private partnerships have grown in number. Integration across 
consortia can be an effective way to tackle challenges such as clinical meaningfulness in 
chronic diseases [17]. To achieve a consensus as efficiently as possible, data-driven paths that 
include the views of academic experts, technical, clinical, and health authority views, as well 
as those of nonprofit organizations and patients, need to be aligned. The objective in achieving 
a framework of integrated consensus building is to include all stakeholder groups working 
together to share costs and risks as well as minimize duplication of efforts. Such a framework 
is also a catalyst given the need to evaluate multiple independent data sets. Progress in the 
use of DHT as medical devices is advancing given the regulatory approval of specific devices 
such as the Parkinson’s KinetiGraph [18] and BioStamp nPoint/MC10 [19]. In the current 
climate of the COVID-19 crisis, there will be a growing acceptance for the use of highly capable 
commercial devices demonstrated to be fit for purpose for an intended application [20]. Out 
of scope for this review is the use of DHT as medical devices for an intended use and in 
decision making in the course of routine clinical care. The use of DHT to collect patient self-
reported information via electronic platforms (e.g., electronic patient-reported outcomes; 
ePRO) is also out of scope for this review. 
Examples of How Collaborations Can Address Gaps
A broad range of new precompetitive collaborations that have been launched over the 
past several years is now serving to engage and convene diverse stakeholders with expertise 
in DHT with clinical, academic, and industry researchers (e.g., [14, 16, 21–24]). Many of these 
efforts represent true case examples illustrating how precompetitive collaborative activities 
are being employed efficiently to address challenges in the field. The examples that follow are 
a subset of multiple initiatives to highlight how collaborations can address gaps in the appli-
cation of DHT with PD as the key focus; see Table 2 for a high-level summary.
The Digital Medicine Society
One notable example that crosses many disease areas is the Digital Medicine Society 
(DiMe), which represents the first professional organization of experts from all disciplines 
comprising the diverse field of digital medicine. The DiMe is a non-profit organization dedi-
cated to advancing digital medicine to optimize human health. It serves professionals at the 
intersection of the global healthcare and technology communities, supporting them in devel-
oping digital medicine through interdisciplinary collaboration, research, teaching, and the 
promotion of best practices. Since launching in 2019, the DiMe has engaged a diversity of key 
stakeholders and is aggressively tackling issues that are cross cutting and leading to recom-
mendations for the field as a whole to follow. Three examples of recent impact include: recom-
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mendations for evaluation and performance of a DHT based on verification, analytical vali-
dation, and clinical validation [22]; the development of a practical guide for evaluating fit-for-
purpose commercialized products across biomedical research and clinical care [25]; and the 
development of a framework to guide the selection and development of digital measures of 
health that matter to patients [26]. The DiMe has developed a crowdsourcing library of digital 
endpoints focused on industry-sponsored studies of new medicinal products comprised of 
137 individual entries, including PD, as of October 2020 [27].
Parkinson’s Progression Markers Initiative 
The Parkinson’s Progression Markers Initiative (PPMI) is a multicenter longitudinal 
study designed to comprehensively assess PD progression, clinical outcomes, imaging, digital, 
genetic, and biological biomarkers [28]. The study, which enrolled its first subject in 2010, is 
sponsored by the Michael J. Fox Foundation and it is supported in part by a precompetitive 
consortium that includes 29 industry and nonprofit partners. The PPMI data are openly 
shared as they are acquired through the PPMI website [28], with more than 5 million down-
loads recorded as of 2019. The impact of the PPMI continues to expand, and much of the 
success can be attributed to agreement on consensus data standardization and open sharing 
of all patient-level data with the broad community. Two distinct digital device platforms, i.e., 
the Verily and Roche platforms, are being utilized in PPMI subjects enrolled in USA and select 
non-USA sites, respectively. The Roche platform, developed by their Pharma Research and 
Early Development group, is a smartphone-based system that assesses PD function continu-
ously via active monitoring of voice, balance, gait, dexterity, resting tremor, and postural 
tremor while participants perform a series of tasks [12, 29]. Metrics under passive moni-
toring, such as time spent walking and sit-to-stand transitions, are collected as participants 
go about daily activities. The technology has been incorporated into a phase 2 clinical trial 
targeting α-synuclein [12], in addition to being integrated into the PPMI multisite global 
observational study. The Verily platform consists of a highly advanced smartwatch developed 
by Verily Life Sciences. The Verily Study Watch enables the collection of physiological and 
environmental data about acceleration/orientation, pulse rate, electrodermal activity, elec-
trocardiogram (ECG), barometric pressure, relative humidity, environmental temperature, 
and ambient light level [30]. PPMI will make digital data from both platforms available to 
researchers with the goal of advancing independent studies and accelerate the generation of 
knowledge in Parkinson therapeutic development. The PPMI platform sets a precedent for 
other diseases to follow to enable open science and transparency.
Personalized Parkinson Project
The Personalized Parkinson Project (PPP) is a single-site observational study being 
carried out with participants throughout The Netherlands [31]. The PPP study is deploying 
the Verily smartwatch developed by Verily Life Sciences, which has now been worn by 500 
patients, 260 of whom have already worn the device for more than a year, and more than 60 
patients who have already worn it for more than 2 years. The Verily study watch measures a 
variety of physiological and environmental parameters on a continuous basis [27]. Since the 
start of 2020, participants also complete weekly “virtual motor examinations” at home – a 
series of 7 motor tasks while wearing the smartwatch – to capture bradykinesia, tremor, gait, 
and posture under controlled circumstances, but still at home. All participants also complete 
a full neurological examination annually, during both an OFF and an ON state, while wearing 
the smartwatch. Participants also annually receive a complete ECG as well as a Holter ECG, 
while wearing the smartwatch. Importantly, the dropout rate in the entire study continues to 
be exceptionally low at just 1% even after 3 years into the study, and the average wear time 
of the watch is 22 h/day. The platform being employed in The Netherlands was designed to 
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ensure a comprehensive focus on patient privacy, security, and compliance with all current 
regulations. An additional attribute of this study is that the PPP investigators aligned with the 
PPMI study investigators to enable alignment of standard operating procedures and data 
acquisition parameters such that that the results can be compared and integrated across 
studies. Opportunities to leverage this experience exist to maximize compliance in other 
studies. The PPP represents a unique study to begin developing digital outcome biomarkers 
for PD. Study data, including the raw sensor data from the smartwatch, will become available 
for scientists to address PD-related research questions. 
Oxford Parkinson’s Disease Centre Discovery Cohort
The multisite deep phenotyping study of the Oxford Parkinson’s Disease Centre (OPDC) 
Discovery Cohort in the UK has successfully deployed smartphones for use in detecting and 
monitoring symptoms of PD, first in a pilot study of PD subjects and then in the largest cohort 
of at-risk individuals for development of PD, i.e., those with idiopathic REM sleep behavioral 
disorder [32]. This study is distinct in that it represents the evaluation of smartphone assess-
ments in one of the largest cohorts of deeply phenotyped participants with idiopathic REM 
sleep behavioral disorder, PD, and healthy volunteers. This large cohort has only been possible 
due to the collaboration of multiple sites with the OPDC, and it addresses the urgent need for 
early detection of disease progression. The results demonstrated that objective quantifi-
cation of motor symptoms using smartphones can be used to discriminate between partic-
ipant groups with a high level of accuracy [32]. Postural and rest tremor were reported to be 
the most salient factors in discriminating idiopathic REM sleep behavioral disorder patients 
from controls. Successful deployment of remote monitoring technologies for identification of 
those who are likely to develop synucleinopathies has true potential for enabling early inter-
vention strategies. The OPDC Discovery Cohort also used smartphones to predict the onset of 
clinically relevant endpoints in early PD subjects, including new-onset falls, freezing, postural 
instability, and cognitive and functional impairment at 18 months [33].
Michael J. Fox Foundation Digital Health Consortium
The Michael J. Fox Foundation convened a group of leading experts with the objective of 
improving the development of therapeutics for PD through the use of reliable digital endpoints. 
One gap that has been highlighted in the area of DHT is the lack of open-access consensus data 
standards that have been accepted by the community [34]. A diverse working group of data 
scientists, pharmaceutical companies, and data standard consortium partners codeveloped a 
comprehensive roadmap for metadata standards for DHT. This collaboration ensured that 
the proposed metadata set was in line with the existing needs of both research and clinical 
and industry stakeholders in addition to existing regulatory recommendations. Thus, the 
metadata standard will increase the interoperability of datasets and allow for pooling datasets 
in the process of validating and interpreting DHT for regulatory acceptance. The metadata set 
was developed specifically in the context of PD [35] as a model for a wide range of other 
chronic disease conditions where remote monitoring will be impactful to advance public 
health.
Movement Disorders Society Task Force on Technology
The Movement Disorders Society (MDS) Task Force on Technology is comprised of 
leading experts across different disciplines led by distinguished movement disorder experts 
with the goal of advancing PD research and care. The group aims to appraise the extent to 
which technology and data analysis can lead to actionable pharmacological and nonpharma-
cological therapeutics for clinical applications. A comprehensive review by the MDS task force 
effectively outlined gaps and opportunities [14]. A roadmap has been developed that outlines 
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recommendations for assessing readiness for deployment of promising devices and algo-
rithms for implementation [21]. While clinical and academic studies signify the importance 
of precompetitive collaborations among multidisciplinary stakeholders in addressing the 
existing barriers to advancing DHT for use in PD trials, alone they are not enough.
In order for precompetitive collaborations to make meaningful progress, it is important 
to engage with regulatory agencies early on and to implement regulatory science into the 
design of these studies to catalyze the use of DHT in drug trials.
MDS Study Group on Telemedicine
The MDS Study Group on Telemedicine aims to harmonize efforts to use telemedicine 
approaches as a way of improving care for patients with PD and other movement disorders 
[36]. There is considerable focus on the use of videoconferencing, in particular to support 
patients living in remote or otherwise underserved areas. Stimulated by the unfolding 
COVID-19 pandemic, this study group has also provided recommendations for the use of tele-
medicine to ascertain continuity of care for patients who are now grounded at home to 
mitigate the risk of contagion [37]. Although the focus is primarily on optimizing care delivery, 
many of the insights will undoubtedly prove to be useful to innovate clinical trial designs as 
well.
Innovative Medicines Initiative Mobilise-D
Mobilise-D (Connecting digital mobility assessment to clinical outcomes for regulatory 
and clinical endorsement; www.mobilise-d.eu) is one of the leading programs aiming to 
deliver a solution for remote digital assessment of mobility [38]. Mobilise-D is a public-private 
partnership funded by the European Innovative Medicines Initiative 2 Joint Undertaking. The 
Mobilise-D consortium includes 34 international research partners based at leading univer-
sities, SME, and some of the world’s largest pharmaceutical and technical companies. The 
partners in Mobilise-D are collaborating to address the critical challenges to turn digital 
mobility assessment into a reality in clinical trials and ultimately healthcare. The overarching 
objective of Mobilise-D is to obtain regulatory approval for the use of digital mobility outcomes 
in a variety of disease states – i.e., PD, chronic obstructive pulmonary disease, multiple scle-
rosis, and proximal femoral fracture. Mobilise-D is taking an integrated approach to tackle the 
critical steps for adoption of digital mobility outcomes from concept, through robust technical 
and clinical validation, to regulatory approval. In order to achieve a lasting legacy, Mobilise-D 
aims to develop standards, disease and hardware agnostic approaches, open access tools, and 
digital databases, among other things, to harmonize working practices and aid further devel-
opment. Embedded stakeholder engagement, external scientific advisory input, and patient 
and public involvement enrich the work of Mobilise-D to ensure maximum impact.
Case Study: Engagement of Regulatory Agencies by Multidisciplinary 
Stakeholders to Advance DHT
In addition to the collaborations highlighted above, the Critical Path Institute has estab-
lished new initiatives under existing disease-specific consortia that are advancing the regu-
latory maturity of DHT. 
The Critical Path Institute is an independent, nonprofit organization established in 2005 
to deliver on the vision of the Critical Path Initiative of the FDA [39]. C-Path serves as a neutral 
convener bringing together diverse stakeholders under a legal, data-driven, and regulatory 
framework to streamline efficiencies in drug development across multiple disease areas [40]. 
The US FDA regularly engages with external public-private partners to contribute to the 
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development of drug development tools, databases, consensus data standards, education/
training modules, and best practice recommendations that aim to address unmet needs [41]. 
C-Path also has strong alliances with the EMA and it has achieved regulatory successes across 
many disease areas with FDA, EMA, and PMDA. 
Critical Path for Parkinson’s (CPP), one of several Critical Path Institute consortia, was 
established as an international consortium of academic institutions, pharmaceutical com- 
panies, patient advocacy organizations, and regulators to collectively advance the devel-
opment of effective treatments for PD by aligning with regulatory agencies and promoting 
excellence in data science using a data-driven research approach [42]. The progress of CPP to 
date includes qualification of dopamine transporter imaging as an enrichment biomarker for 
PD clinical trials in patients with early Parkinsonian symptoms [43], and the development of 
a global integrated unified database of standardized patient level data from clinical studies 
conducted around the world [42]. When CPP was launched, the concept of focusing on digital 
technology was envisioned as a future strategy [42]. In 2018, CPP launched a Digital Drug 
Development Tools (3DT) team. The goal of 3DT is to leverage the unique role of CPP as a 
neutral convener to bring stakeholders together in a precompetitive space to collectively 
engage with regulatory agencies in an iterative path to optimize the effective use of DHT in 
PD clinical trials. 
The CPP 3DT team represents a subset of CPP member organizations (a total of 7 industry 
organizations as of 2020) [44]. The 3DT members are collaborating precompetitively to 
optimize the efficiency of paths for developing digital tools for PD drug development. This 
team focuses on engaging regulators early and collecting data from DHT prospectively. The 
nucleus of 3DT is a prospective observational study called Wearable Assessments in the Clinic 
and Home in PD (WATCH-PD), funded by member companies. WATCH-PD is a 12-month 
multicenter, longitudinal, digital assessment study of PD progression in subjects with early 
untreated PD (online suppl. Table 1; see www.karger.com/doi/10.1159/000512500 for all 
online suppl. material). The primary goal is to generate and optimize a set of candidate 
objective digital measures to complement standard clinical assessments in measuring the 
progression of disease and the response to treatment. A secondary goal is to understand the 
relationship between standard clinical assessments, research grade digital tools used in a 
clinical setting, and more user-friendly consumer digital platforms to develop a scalable 
approach for objective, sensitive, and frequent collection of motor and nonmotor data in early 
PD. The study was amended, based on the regulatory feedback described below, to include a 
cohort of age-matched normal subjects without PD as a parallel substudy to assess perfor-
mance in normal subjects.
3DT has engaged regulators in interactive forums starting early in the project, using 
WATCH-PD as a pilot study around which to focus discussion. A Critical Path Innovation 
Meeting (CPIM) [45] on digital drug development tools for PD was held with the FDA in May 
2019 on behalf of 3DT, with participating FDA staff representing 9 different offices from 
across the agency. CPIMs were established by the FDA to provide informal opportunities for 
discussing innovative drug development approaches, methodologies, and technologies. The 
CPIM is a means by which the FDA Center for Drug Evaluation and Research (CDER) and 
investigators from industry, academia, scientific consortia, patient advocacy groups, and 
government can communicate to improve efficiency and success in drug development. The 
CPIM framework represents a nonbinding platform to discuss a methodology or technology 
and its potential utility to enhance drug development.
Similar opportunities are available for meeting with the EMA through their Innovation 
Task Force (ITF) platform [46]. ITF meetings foster early dialogue on scientific, legal, and 
regulatory issues of emerging therapies and technologies, including digital technologies. The 
CPP 3DT team engaged the EMA on DHT in an ITF meeting held in July 2019.
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Both the FDA and the EMA expressed support for the CPP 3DT team engaging with regu-
lators early by way of a consortium approach. The concept of collaborating early and focusing 
on a defined prospective pilot study was also positively perceived. The following topics were 
emphasized by both regulatory agencies:
 • The importance of properly evaluating clinically meaningful aspects of motor, non-motor, 
and mood-related manifestations of PD
 • The importance of assessing patients’ perspective on how digital measures assess how 
patients function and feel
 • A recommendation to conduct exit interviews to gather patient feedback on their expe-
rience with DHTs
 • The importance of establishing normative databases of metrics that will be collected with 
wearable devices
 • A suggestion that it may be beneficial to enroll subjects at the earliest point possible in 
disease progression to identify sensitive measures that are uniquely applicable to early 
PD
 • Concern about patient adherence with at-home data collection approaches and data 
quality
 • Technical issues related to the impact of hardware/software changes on results, data 
quality issues, how to address missing data, and the need for transparency of algorithms
 • The importance of context and accounting for environmental factors with in-home 
remote assessments
 • Establishment of clinical meaningfulness of concepts being measured and alignment on 
how to assess and interpret changes in digital measures.
The EMA and FDA advised that the 3DT team proceed by adopting the recommendations 
and reengaging the agencies for formal review with data from multiple independent studies 
that will inform the appropriate target population, context of use, concept of interest, and 
technical validation steps needed for the future. A recommendation from the FDA was to 
work directly with the Office of Neuroscience of the Center of Drug Evaluation and Research 
and in particular with the Division of Neurology I, which regulates and reviews investiga-
tional new drug applications and marketing applications for drug and biologic products for 
the treatment of neurological diseases and conditions, such as Alzheimer disease, stroke, PD, 
Huntington disease, epilepsy, pain, muscular dystrophy, amyotrophic lateral sclerosis, 
multiple sclerosis, dementia, and narcolepsy. 
The EMA recommendeds taking a stepwise approach, starting with the identification of 
small, well-defined, meaningful measures followed by a data-driven development path. When 
data become available, the CPP 3DT team will be poised to return to the EMA for scientific 
advice regarding the potential for qualification of digital measures. The EMA recommended 
use of the formal path defined as “qualification of novel methodologies for medicine devel-
opment,” a voluntary scientific pathway to evaluate novel methodologies (e.g., biomarkers, 
clinical outcome assessments, imaging methods, new animal models, statistical methods, 
innovative trial methodologies, big data approaches, etc.) to formally advance the regulatory 
acceptability of a specific use of a methodology for the development of medicinal products. 
The 3DT team has embarked on the next steps of its device-agnostic approach and is 
proceeding as advised with the goal of having the data inform the concepts of interest and 
context of use. It is anticipated that a data-driven approach and assessment of multiple inde-
pendent studies will enhance alignment with healthcare regulators and effective use of DHT 
in PD trials.
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Regulatory Science as a Catalyst to Advance the Development of DHT
Regulatory science pathways serve to incentivize industry to align on best practices and 
adhere to standardized data collection and analytical approaches to ensure overall scientific 
rigor and clinical validity for regulatory decision making. The attention to digital technologies 
is featured in global regulatory agency strategic initiatives.
European Medicines Agency
The EMA clearly highlighted the importance of DHT in their “Regulatory Science to 2025” 
strategy document, which included the goal of exploring the application of innovative digital 
technologies to support data-driven decisions [47]. The EMA has issued a qualification 
opinion on the use of a valid and suitable wearable device to be used in Duchenne muscular 
dystrophy clinical trials [48, 49]. Stride velocity 95th centile measured at the ankle was 
deemed an acceptable secondary endpoint in pivotal or exploratory drug therapeutic studies 
for regulatory purposes [50].
More recently, the EMA has outlined a framework for success in reference to deploy-
ment of DHT in clinical trials [51]. Recommendations include the following: (1) early inter-
action with the EMA to maximize knowledge and align across multidisciplinary teams; 
(2) employment of an iterative process to establish proof of concept followed by more 
extensive valuation of the technology; (3) identification of a clear research question; 
(4) attention to technologic parameters; (5) provision of appropriate documentation such 
as reliability, repeatability, accuracy, clinical validity, generalizability, and clinical applica-
bility of the methodology; and (6) active encouragement and support from the EMA of advice 
being sought by collaborative groups such as consortia. Note that the EMA recommends that 
the qualification of novel methodologies serve as the platform to formally endorse the use 
of DHT in trials. In May 2020, the EMA issued a questions and answers guidance titled “Qual-
ification of Digital Technology-Based Methodologies to Support Approval of Medicinal 
Products” that outlines concise recommendations under the Qualification of Novel Method-
ologies Program [52].
US Food and Drug Administration
For the FDA, there are is a growing number of examples that include the use of DHT, such 
as the patient-focused drug development public workshops and guidances [53], and disease-
specific guidances, such as in amyotrophic lateral sclerosis, where DHT were included for 
identifying and monitoring patients [54]. The concept of real-world evidence and decen-
tralized clinical trials is advancing rapidly, with innovative regulatory science frameworks 
being communicated broadly [55].
As of July 2020, there were a total of 7 digital outcomes under review in the Clinical 
Outcome Assessment (COA) Qualification Program as digital endpoints [56].
Beyond CPP/3DT, the FDA has provided formal advice to sponsors aiming to qualify the 
use of DHT as digital endpoints in clinical trials. These examples span a wide range of chronic 
diseases, including Duchenne muscular dystrophy, multiple sclerosis, heart failure, pain, and 
sarcopenia. Under the 21st Century Cures Act there is transparency of materials under regu-
latory review for qualification of drug development tools [57, 58]. This development enables 
enhanced learning opportunities for stakeholders to get a better sense of expectations for 
successfully advancing these tools for use in drug development. It is acknowledged that each 
example has unique contexts of use, yet it is likely that valuable information can be extracted 
to enhance the learnings and to benefit the community as a whole. 
Table 3 gives insight into feedback provided by the FDA on COA qualification submissions 
under review that focus on DHT (passive monitoring digital COA) [56]. The column lists 
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specific recommendations that were communicated to submitters as written responses to the 
letters of intent accepted into the qualification program.
The feedback in Table 3 was extracted from the responses to the letters of intent across each 
of the submissions. Additionally, more detailed feedback that is specific for that indication and 
context of use is not included in this table; online supplementary Table 2 provides a compre-
hensive list of specific feedback across the various submissions. The FDA feedback was quite 
consistent across the individual disease area examples. Common themes included recommenda-
tions to carry out test-retest measures for reliability, provide a complete description of the 
device, algorithm input and output, and outline plans for determination for meaningful interpre-
tation of change in patients and patient input to determine important concepts and aspects for 
the defined target population when designing DHT studies. Separate from the FDA formal qual-
ification pathway described above, an FDA review division pathway also may be utilized to reach 
alignment on acceptance for use of specific tools such as a DHT in clinical trials. 
Table 3. Key issues highlighted to submitters advancing digital COA for FDA qualification


























Clear definition of endpoint ✔ ✔ ✔
Patient input to determine the most important concepts and 
aspects
✔ ✔ ✔ ✔ ✔
Consider including those who use assistive walking devices/
nonambulatory patients in the target population ✔ ✔ ✔
Test-retest to demonstrate measurement reproducibility ✔ ✔ ✔ ✔ ✔
Adequate content validity ✔ ✔ ✔ ✔
Meaningful interpretation of variable change over time/
translation of the assessed outcome into how the patient feels 
or functions/what would be a meaningful change for patients ✔ ✔ ✔ ✔
Effect of the sensor’s weight and dimension/wearing on patient 
movement/compliance
✔ ✔
Information on dimensions/size/weight of the sensor ✔ ✔ ✔
Description of the device, algorithm, input and output ✔ ✔ ✔ ✔ ✔ ✔
Instructions on how to use the device/details of device use ✔ ✔ ✔
Mathematical basis of the minimum acceptable amount of 
time for measurement/sufficient time duration for measurement ✔ ✔
Demonstration of consistency and uniformity in measurements 
over time in comparison to a reference value ✔ ✔
Usability testing ✔ ✔ ✔
Data loss minimization plan ✔ ✔
Plans for assessing and handling missing data ✔ ✔
Specify patients’ current activity to be referenced as baseline and 
used for comparison after intervention ✔ ✔ ✔
Assess the effect of differences in placement of the device ✔ ✔ ✔
Uncontrolled sources of variability should be taken into 
consideration ✔
Specific recommendations from the FDA for qualification submissions currently under review for application of DHT for specific contexts of use are shown. Numbers 
refer to the actual number assigned to individual submissions. 1 Feedback ID: No. 000106. 2 Feedback ID: No. 000105. 3 Feedback ID: No. 000102. 4 Feedback ID: No. 
000114. 5 Feedback ID: No. 000103. 6Feedback ID: No. 000120. More details can be found in online suppl. Table 2.
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Future Directions
The future for the advancement of digital technologies in PD is evolving in parallel with 
the rapid growth of the DHT landscape. The medical device and pharmaceutical industries 
have been working with research and clinical specialists, and patient organizations in multiple 
disease areas. Regulatory agencies serve a unique role to craft a framework that will guide 
efficient development of reliable and valid digital tools, recognizing the common challenges 
and opportunities faced across disease areas. 
The convergence of interest in DHT from multiple stakeholder groups reflects the fact 
that these devices may enable the collection of clinically meaningful data from individual 
patients in their everyday lives. Thus, they offer opportunities to advance precision medicine. 
However, DHT raise substantial challenges including harmonization, standardization, vali-
dation, data storage and sharing, and privacy. Individual stakeholder groups are providing 
insightful recommendations for how some of these gaps can be addressed (e.g., [59, 60]). 
Tackling challenges collectively by advancing data-driven solutions and sharing costs and 
risks, as well as embracing open science, will be key to accelerating the adoption and regu-
latory acceptance of DHT and their use in clinical trials.
Recommendations from the CPP Consortium
The CPP outlines the following recommendations based on the collective learnings of the 
Critical Path Institute in leading multiple consortia across many disease areas focused on 
regulatory acceptance of novel drug development tools: 
 • Focus on what is clinically meaningful to patients as core to all aspects of PD drug devel-
opment and deployment of DHT
 • Build consensus on data and metadata standards that will facilitate data exchangeability 
and data pooling across different research and clinical trials 
 • Develop open-source platforms for analysis and deploy across device types and studies
 • Explore opportunities to deploy remote monitoring technologies to identify individuals 
at risk for development of PD
 • Enable data infrastructure platforms that allow the entire end-to-end workflow of digital 
sensor data to final measurement value
 • Ensure there is transparency with provenance of data from raw data to algorithm from 
digital devices at all stages of the workflow; avoid black-box algorithms
 • Foster paths to encourage algorithmic literacy, transparency, and oversight
 • Adopt best practices as for fit-for-purpose tools aligned with recommendations by profes-
sional societies and regulators
 • Adopt model-informed drug development regulatory paths by using DHT as sensitive 
tools to quantify disease progression
 • Engage early and often with regulatory agencies via consortia that enable data sharing 
across multiple independent studies in a device-agnostic way
 • Align directly with the review division at FDA and utilize EMA qualification of novel 
methodologies for medical product development
 • Consider multiple applications of DHT in drug development, including monitoring of 
disease progression, identification of subjects at early stages of PD, dose selection in 
phase 1 clinical trials, and proof-of-concept decision making
 • Align across relevant PD precompetitive initiatives to synergize efforts, enhance learnings, 
and avoid duplication of effort
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A graphical illustration of the various components of the digital technology strategy of 
the CPP is highlighted in Figure 1. Key components include a focus on the voice of the patient 
and early and frequent engagement with regulatory agencies and open science. 
In summary, there are many diverse and impactful applications of how consensus 
building can further the effective use of DHT in advancing new treatments for PD. It is 
important for diverse applications to be pursued in parallel to maximize the learnings and 
experience across all platforms. Expertise across all stakeholders is required to address the 
challenges, and inclusion of regulatory agencies as part of the stakeholder community is 
encouraged. Alignment across efforts is needed to enhance, synergize, and minimize dupli-
cation of efforts to advance therapies that can employ DHT and provide much needed benefit 
for those living with PD. 
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tory acceptance and adoption in clinical trials. The original focus on the voice of the patient facilitates the 
identification of clinically meaningful concepts of interest. Data standardization and definition of sources of 
variability are key to early steps to engage regulatory agencies. Implementation in PD trials is envisioned 
(right) when the steps to the left are followed.
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